☰

Adamed Pharma S.A.

Scaling to 4 billion tablets

A Polish manufacturer running electronic batch records across two sites, producing 2 billion tablets a year

Industry
Pharmaceutical Manufacturing
Headquarters
Piechowice, Poland
Public information as of
January 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of Adamed Pharma S.A.'s published strategy and is not endorsed by, or produced in cooperation with, Adamed Pharma S.A.. Company website

Strategic priorities

Adamed is a Polish pharmaceutical manufacturer headquartered in Piechowice, operating production facilities in Pabianice and Ksawerów with a PEL 300 million Production and Logistics Centre expansion underway. The company produces 2 billion tablets annually across 900 SKUs and is scaling to 4 billion tablets by 2027 — a doubling of production capacity that requires corresponding investments in automation, digital infrastructure, and workforce readiness.

Adamed is implementing Siemens Opcenter Execution Pharma MES with electronic batch records across packaging areas while maintaining integration with SAP S/4HANA, LIMS, and industrial automation systems. The company is the highest-robotisation pharmaceutical manufacturer in Poland, with robot-aided manufacturing for palletising and packaging already deployed. The High Potent Zone handles steroids and oncological drugs with OEB 4-5 requirements.

The PLN 500 million inhalation platform investment through 2030 targets DPI and MDPI inhaled products with first commercial products expected in 2031 — requiring simultaneous engineering of chemical formulations and mechanical delivery devices that will stress the digital infrastructure designed for small molecule manufacturing.

Challenges we see

  • Digital Integration IT/OT Convergence

    MES-LIMS integration complexity across three sites

    Adamed's Siemens Opcenter MES, SAP S/4HANA ERP, LIMS, and 12 packaging lines operate across Pabianice and Ksawerów with multiple integration points that demand continuous data flow. Manufacturing downtime in large-scale pharma costs up to USD 6.8 million per hour — integration failures that delay batch release have direct financial impact.

    When the MES and LIMS integration fails, batch release is delayed until the discrepancy is manually investigated and resolved — the manufacturing schedule is disrupted and the production target for 4 billion tablets is at risk of slippage.

  • Lab 4.0 R&D Operations

    Manual laboratory data transcription creating ALCOA+ risks

    The 3,000 sqm R&D Centre in Pieńków and new Kajetany laboratory house advanced analytical equipment — SEM, XRPD, UPLC/MS — that generate high volumes of data requiring integration between R&D, Quality, and Regulatory teams. Manual transcription from instruments to LIMS creates ALCOA+ compliance risks and productivity losses.

    When a regulatory inspector reviews laboratory records and finds transcription discrepancies between instrument outputs and LIMS entries, the finding triggers a CAPA that consumes quality team time and creates a documentation burden that slows the introduction of new analytical methods.

  • Process Control Manufacturing Safety

    High Potent Zone OEB 4-5 compound handling requiring advanced automation

    The High Potent Zone handles steroids and oncological drugs with OEB 4-5 toxicity requirements — demanding specialised control systems and closed-loop automation that prevent human exposure to highly toxic active pharmaceutical ingredients. Manual interventions in the High Potent Zone create contamination and operator safety risks.

    When an operator must enter the High Potent Zone for manual intervention, the facility must be decontaminated before re-entry — the cleaning and re-entry protocol consumes hours of production time and creates operator safety risk that advanced automation would eliminate.

  • New Product Line R&D & Manufacturing

    Inhalation platform scale-up from 50L to commercial volumes

    The PLN 500 million inhalation platform requires scale-up from 50L bacterial and 100L mammalian pilot bioreactors to commercial manufacturing volumes — a scale range that introduces process variability, particle size control challenges, and regulatory complexity that the current digital infrastructure was not designed to manage.

    When the formulation and device co-development for the inhaled product platform requires simultaneous data from chemistry, physics, and mechanical engineering teams, the lack of a unified data platform means each team works from their own data sources — the cross-functional collaboration that inhaled product development requires is hampered by data silos.

  • Logistics Supply Chain

    Energy intensity of new 34,000-pallet warehouse

    The new 34,000-pallet warehouse requires smart infrastructure management and energy monitoring that the current building management systems cannot provide — the energy cost of the expanded facility is a significant operational expense that optimisation could reduce.

    When the warehouse energy consumption is not monitored at the equipment level, the opportunities to reduce energy cost through load shifting, equipment scheduling, and maintenance optimisation are invisible — the facility operates less efficiently than the capital investment would justify.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. LES and laboratory instrument integration for ALCOA+ compliance

    QC and R&D laboratories operate with disconnected equipment — pH meters, balances, UPLC/MS, XRPD — requiring manual transcription to LIMS and creating ALCOA+ compliance risks. The Lab 4.0 transition targets 30-40% productivity gains but disconnected instruments create data silos and audit vulnerabilities.

    Implement a Laboratory Execution System as a Single Source of Truth, connecting analytical instruments directly to LIMS with automated data capture and ALCOA+ compliant audit trails — eliminating manual transcription and ensuring that every measurement is attributable, legible, contemporaneous, and original.

    • Adamed laboratory current state and ALCOA+ gap assessment
    • 3,000 sqm R&D Centre analytical equipment inventory and data flow mapping

  2. IT/OT ecosystem integration for automated batch release

    Multiple execution systems — MES, LIMS, SAP S/4HANA — and industrial automation operate in silos, preventing efficient access to electronic documentation and real-time equipment status. The integration required for fully automated batch release is not yet in place.

    Create a connected digital ecosystem integrating Opcenter MES with LIMS, ERP, and shop-floor automation through standardised OPC UA interfaces — enabling automatic material ordering, electronic batch records, and accelerated batch release across the Pabianice and Ksawerów sites.

    • Adamed MES-LIMS-ERP integration architecture assessment
    • SAP S/4HANA and Opcenter current integration state audit

  3. Robotisation and advanced automation for 4 billion tablet scale

    Doubling production from 2 to 4 billion tablets by 2027 requires advanced robotisation across palletising, packaging, and quality control. Manual palletising creates bottlenecks and the High Potent Zone requires automation that eliminates operator exposure to OEB 4-5 compounds.

    Deploy autonomous palletising robots, inhaler packaging robots, dissolution robots in QC, and smart warehouse infrastructure — maintaining Adamed's position as the highest-robotisation pharmaceutical manufacturer in Poland while enabling the capacity expansion that 4 billion tablets requires.

    • Adamed automation roadmap and capacity expansion plan
    • High Potent Zone automation requirements and OEB 4-5 controls assessment

  4. Predictive maintenance for 12 packaging lines and tablet presses

    Complex manufacturing equipment — tablet presses, 12 packaging lines, High Potent Zone systems — risks unplanned downtime that costs up to USD 6.8 million per hour in large-scale pharmaceutical operations. Manual inspection-based maintenance cannot predict failures before they occur.

    Implement condition-based maintenance with real-time monitoring and anomaly detection across 12 packaging lines and critical tablet presses — reducing manufacturing downtime by 30-50% through early identification of equipment degradation before it causes production failures.

    • Adamed equipment maintenance history and downtime cost analysis
    • Current maintenance approach and predictive monitoring technology feasibility

  5. Digital twin for inhaled product formulation and scale-up

    New DPI and MDPI inhaled product development requires extensive wet-lab experimentation with long development cycles and high costs for failed experiments. Particle size, formulation, and device design interact in complex ways that physical trials alone cannot efficiently optimise.

    Deploy digital twin simulation for bioprocess and formulation development — enabling in-silico optimisation before physical trials, accelerating time-to-market for the pulmonology products targeted for 2031, and reducing the experimental cost of failed formulation iterations.

    • Adamed inhalation platform R&D roadmap and development timeline
    • Current formulation development approach and digital twin feasibility assessment

What we'd propose

  • Digital Lab

    Laboratory Execution System and Digital Lab Transformation

    We implement a Laboratory Execution System connecting Adamed's analytical instruments — UPLC/MS, XRPD, SEM, pH meters, balances — to LIMS with automated data capture and ALCOA+ compliant electronic records — eliminating manual transcription, ensuring regulatory-grade data integrity, and delivering the 30-40% laboratory productivity improvement that the Lab 4.0 programme targets.

    • Automated analytical instrument data ingestion

      UPLC/MS, XRPD, and SEM data captured directly from instruments

      Build automated data pipelines from the analytical instruments — UPLC/MS, XRPD, SEM — directly to LIMS, eliminating the manual transcription step that creates ALCOA+ compliance risks and consuming quality technician time with repetitive data entry.

    • LES with electronic workflow and sample tracking

      Sample chain of custody managed automatically in the LES

      Configure the LES with electronic sample tracking, chain of custody documentation, and automated workflow routing — ensuring that every sample is tracked from collection through analysis to result release with full attribution and timestamp records.

    • ALCOA+ compliance monitoring dashboard

      Data completeness verified automatically across all laboratories

      Deploy a compliance monitoring dashboard that continuously verifies the completeness and attribution of laboratory data across the R&D Centre and Kajetany laboratory — flagging gaps before regulatory inspections surface them and providing the proactive compliance assurance that GxP requires.

    • Regulatory inspections find no ALCOA+ discrepancies because data is captured electronically at the point of generation — the quality team's CAPA burden decreases and the laboratory's regulatory reputation improves.
    • Laboratory productivity improves by 30-40% because technicians spend time on analysis rather than transcription — the same team can handle the increased analytical workload that the 4 billion tablet expansion creates.
    • The LES provides the foundation for real-time release testing — the electronic batch records and analytical data pipelines support the regulatory pathways for real-time quality release that reduce inventory holding time.

    We've done this before

    See how we do Digital Lab
  • Enterprise AI

    MES-LIMS-ERP Integration Platform

    We build the OPC UA-based integration layer connecting Adamed's Opcenter MES, SAP S/4HANA ERP, LIMS, and shop-floor automation into a unified digital ecosystem — enabling automatic material ordering, electronic batch records with cross-system traceability, and accelerated batch release across the Pabianice and Ksawerów sites.

    • OPC UA integration backbone for manufacturing systems

      MES, ERP, LIMS, and automation connected via standardised OPC UA

      Deploy the OPC UA integration backbone that connects the Opcenter MES, SAP S/4HANA, LIMS, and PLC-level automation — enabling the real-time data flow between systems that is required for automated material ordering and electronic batch record completion.

    • Cross-system batch record traceability

      Every batch record traceable across MES, ERP, and LIMS

      Configure the cross-system batch record linkage that traces each batch from raw material receipt through manufacturing in MES to quality release in LIMS and financial booking in SAP — providing the complete batch history that regulators and pharmaceutical clients require.

    • Automated release workflow with electronic signatures

      Batch release workflow completed with electronic sign-off

      Build the automated batch release workflow that routes a completed electronic batch record through QA review and electronic sign-off — eliminating the paper-based release process that requires physical document transport and manual filing.

    • Batch release time decreases because the electronic workflow eliminates manual document transport and manual data reconciliation between systems — the production schedule for 4 billion tablets is supported by faster release cycles.
    • Manufacturing downtime caused by integration failures decreases because the OPC UA integration layer is standardised and monitored — the USD 6.8 million per hour cost of unplanned downtime is better protected.
    • The MES-LIMS-ERP integration enables pharmaceutical client audit readiness — the electronic batch record traceability that major pharmaceutical clients increasingly require is demonstrable on demand.

    We've done this before

    See how we do Enterprise AI
  • Digital CDMO

    Robotisation and Advanced Automation Platform

    We design and deploy autonomous manufacturing systems for Adamed's capacity expansion to 4 billion tablets — robot-aided palletising, inhaler packaging automation, automated dissolution testing, and High Potent Zone closed-loop control — maintaining Adamed's position as Poland's most advanced pharmaceutical manufacturer.

    • Autonomous palletising and smart warehouse robots

      Warehouse palletising automated with robot systems

      Deploy autonomous palletising robots in the new 34,000-pallet warehouse — eliminating the manual palletising bottleneck and ensuring that the expanded production capacity is matched by warehouse throughput.

    • Inhaler packaging automation for DPI and MDPI products

      Inhaled product packaging built for the PLN 500M platform

      Configure inhaler packaging robots for the DPI and MDPI inhaled product portfolio — the automation required for the 2031 commercial launch of the inhalation platform is designed and deployed in coordination with the formulation development timeline.

    • Automated dissolution testing in QC laboratory

      Dissolution testing automated to match 4 billion tablet production scale

      Deploy automated dissolution testing robots in the quality control laboratory — enabling the increased QC testing throughput that 4 billion tablet production requires without proportional expansion of QC technician headcount.

    • The 4 billion tablet production target is achievable because warehouse throughput and QC testing capacity scale with production — the bottleneck that would otherwise limit capacity is addressed by automation.
    • Operator safety improves in the High Potent Zone because closed-loop automation reduces the frequency of human entry into OEB 4-5 areas — the safety risk profile for oncological drug manufacturing is reduced.
    • Manufacturing efficiency improves because robots operate continuously without the fatigue and variation that affect human operators — the tablet press and packaging line OEE improves toward theoretical maximum.

    We've done this before

    See how we do Digital CDMO
  • Digital CDMO

    Condition-Based Maintenance Platform

    We implement a condition-based maintenance framework with real-time monitoring and AI-driven anomaly detection across Adamed's 12 packaging lines, tablet presses, and High Potent Zone systems — identifying equipment degradation before it causes unplanned downtime and reducing manufacturing losses by 30-50%.

    • Real-time equipment health monitoring across 12 packaging lines

      Every packaging line monitored for degradation signatures

      Deploy real-time health monitoring on all 12 packaging lines and critical tablet presses — vibration, temperature, power consumption, and throughput patterns are continuously analysed to identify the signatures of developing equipment problems.

    • AI anomaly detection for early failure prediction

      Equipment failures predicted before they cause production stoppages

      Train anomaly detection models on historical equipment failure data — identifying the sensor patterns that precede bearing failures, drive belt wear, and alignment problems, and alerting the maintenance team before the failure occurs.

    • Maintenance workflow automation and spare parts optimisation

      Maintenance work orders generated automatically from equipment health data

      Configure automated maintenance workflow generation from equipment health alerts — work orders are created, assigned, and scheduled based on equipment condition rather than calendar-based preventive maintenance intervals, ensuring that maintenance resources are deployed where they are most needed.

    • Unplanned downtime is reduced by 30-50% because equipment failures are identified and addressed before they cause production stoppages — the USD 6.8 million per hour cost of downtime is mitigated across all production lines.
    • Maintenance resources are deployed more efficiently because condition-based scheduling replaces calendar-based preventive maintenance — the same maintenance team manages more equipment more effectively.
    • The High Potent Zone equipment is monitored continuously for the degradation signatures that would precede a containment failure — the OEB 4-5 safety posture is strengthened by predictive visibility into equipment integrity.

    We've done this before

    See how we do Digital CDMO
  • Enterprise AI

    Digital Twin and Process Simulation for Inhalation Platform

    We deploy a digital twin simulation platform for Adamed's inhalation product development — physics-based and data-driven models of DPI and MDPI formulation behaviour, particle size dynamics, and delivery device performance that enable in-silico optimisation before physical trials, accelerating the 2031 commercial launch timeline.

    • Formulation digital twin for DPI particle size optimisation

      Particle size and aerodynamic performance predicted in simulation

      Build physics-based digital twin models of DPI formulation behaviour — predicting particle size distribution, aerosolisation performance, and delivery efficiency from formulation composition before physical prototype batches are manufactured.

    • Device-formulation co-simulation for MDPI development

      Delivery device and formulation optimised together in simulation

      Configure co-simulation models that combine delivery device mechanical performance with formulation physics — enabling the device design team and formulation team to optimise the system together in simulation rather than through iterative physical prototyping.

    • Scale-up simulation from 50L pilot to commercial volumes

      Commercial scale manufacturing parameters predicted from pilot data

      Build scale-up simulation models that predict commercial manufacturing outcomes from 50L pilot bioreactor data — identifying the process parameter adjustments required for successful scale-up before the commercial batch is attempted.

    • Time-to-market for the first inhaled product is accelerated because formulation iterations that would take months of physical testing are replaced by in-silico screening — the 2031 commercial launch target is more achievable with a digital twin platform.
    • Development cost is reduced because failed formulation experiments are identified in simulation rather than in the laboratory — the PLN 500 million investment in the inhalation platform is protected by better information about which formulations are worth pursuing.
    • The scale-up simulation reduces the risk of a failed first commercial batch — the investment in commercial manufacturing capacity is protected by the predictive visibility that the digital twin provides.

    We've done this before

    See how we do Enterprise AI

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what Adamed Pharma S.A.'s own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Laboratory Digitalization 45 → 90
Analytical instruments — UPLC/MS, XRPD, SEM — are not integrated with LIMS. Manual transcription creates ALCOA+ compliance risks and productivity losses. The LES required to connect the laboratory instrument ecosystem and deliver 30-40% productivity improvement has not been implemented.
Manufacturing Automation 55 → 95
Adamed is the highest-robotisation pharmaceutical manufacturer in Poland, but the 4 billion tablet expansion requires additional automation in warehouse, packaging, and QC. The inhalation platform automation requirements for 2031 are not yet designed.
IT/OT Integration 50 → 90
Opcenter MES, SAP S/4HANA, and LIMS operate with integration points that are not yet fully automated. The OPC UA integration backbone required for real-time cross-system batch traceability has not been deployed.
Predictive Analytics 30 → 80
Condition-based maintenance is not implemented across the 12 packaging lines and tablet presses. The anomaly detection models required to predict equipment failures before they occur have not been trained or deployed.
Process Simulation 25 → 75
Digital twin simulation for the inhalation platform has not been built. Formulation development relies on physical experimentation rather than in-silico screening. The 2031 commercial launch timeline is dependent on accelerating development cycles through digital twin capability.
Data Governance 40 → 85
Data governance across the Pabianice, Ksawerów, and Kajetany sites is managed through site-specific procedures. The cross-site data standards and governance framework required for integrated production planning and batch release have not been implemented.

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of January 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with Adamed Pharma S.A., and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].